(Total Views: 580)
Posted On: 02/15/2025 12:26:03 AM
Post# of 154593
3/01/2023 Leronlimab NASH trial:
57 Vs 30 placebo trial.
(700/350/Placebo)
As usual, there are no Leronlimab post trial FDA issues in our SEC filings.
https://clinicaltrials.gov/study/NCT04521114?...tent-panel
Feb. 06, 2025:
" The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab
--- "monotherapy" --- (compared to an isotype IgG4 control arm with p-values across all 3 studies < 0.01).
Tested against:
Placebo. Resmetirom. Semaglutide. Streptozocin. CCL4.
A 3rd party trial should now be larger than 57 Leronlimab patients.
& looking forward to agreements on "other organs".
57 Vs 30 placebo trial.
(700/350/Placebo)
As usual, there are no Leronlimab post trial FDA issues in our SEC filings.
https://clinicaltrials.gov/study/NCT04521114?...tent-panel
Feb. 06, 2025:
" The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab
--- "monotherapy" --- (compared to an isotype IgG4 control arm with p-values across all 3 studies < 0.01).
Tested against:
Placebo. Resmetirom. Semaglutide. Streptozocin. CCL4.
A 3rd party trial should now be larger than 57 Leronlimab patients.
& looking forward to agreements on "other organs".
(3)
(0)
